Acute Neonatal Effects of Cocaine Exposure During Pregnancy | Infectious Diseases | JAMA Pediatrics | JAMA Network
[Skip to Navigation]
Sign In
September 2005

Acute Neonatal Effects of Cocaine Exposure During Pregnancy

Author Affiliations

Author Affiliations: Department of Pediatrics, University of Miami School of Medicine, Miami, Fla (Dr Bauer); Research Triangle Institute, Research Triangle Park, NC (Mr Langer); Department of Pediatrics, Wayne State University School of Medicine, Detroit, Mich (Dr Shankaran); Department of Pediatrics, University of Tennessee, Memphis, College of Medicine (Dr Bada); Department of Pediatrics, Brown Medical School, Women’s and Infants’ Hospital, Providence, RI (Dr Lester); National Institute of Child Health and Human Development, Bethesda, Md (Dr Wright); The George Washington University Biostatistics Center, Washington, DC (Ms Krause-Steinrauf and Dr Verter); National Institute on Drug Abuse, Bethesda (Dr Smeriglio); Center for Substance Abuse Treatment, Washington (Dr Finnegan); and Administration on Children, Youth, and Families, Washington (Dr Maza). Dr Bada is now at the University of Kentucky, Lexington. Dr Finnegan is now at the Office of Research on Women’s Health, National Institutes of Health, Bethesda.

Arch Pediatr Adolesc Med. 2005;159(9):824-834. doi:10.1001/archpedi.159.9.824

Objective  To identify associations between cocaine exposure during pregnancy and medical conditions in newborn infants from birth through hospital discharge.

Design  Multisite, prospective, randomized study.

Setting  Brown University, University of Miami, University of Tennessee (Memphis), and Wayne State University.

Subjects  A total of 717 cocaine-exposed infants and 7442 nonexposed infants.

Main Outcome Measures  Results of physical examination and conditions observed during hospitalization.

Results  Cocaine-exposed infants were about 1.2 weeks younger, weighed 536 g less, measured 2.6 cm shorter, and had head circumference 1.5 cm smaller than nonexposed infants (all P<.001). Results did not confirm previously reported abnormalities. Central and autonomic nervous system symptoms were more frequent in the exposed group: jittery/tremors (adjusted odds ratio, 2.17; 99% confidence interval, 1.44-3.29), high-pitched cry (2.44; 1.06-5.66), irritability (1.81; 1.18-2.80), excessive suck (3.58; 1.63-7.88), hyperalertness (7.78; 1.72-35.06), and autonomic instability (2.64; 1.17-5.95). No differences were detected in organ systems by ultrasound examination. Exposed infants had more infections (3.09; 1.76-5.45), including hepatitis (13.46; 7.46-24.29), syphilis (8.84; 3.74-20.88), and human immunodeficiency virus exposure (12.37; 2.20-69.51); were less often breastfed (0.26; 0.15-0.44); had more child protective services referrals (48.92; 28.77-83.20); and were more often not living with their biological mother (18.70; 10.53-33.20).

Conclusions  Central and autonomic nervous system symptoms were more frequent in the exposed cohort and persisted in an adjusted analysis. They were usually transient and may be a true cocaine effect. Abnormal anatomic outcomes previously reported were not confirmed. Increased infections, particularly sexually transmitted diseases, pose a serious public health challenge. Exposure increased involvement of child protective services and out-of-home placement.

Drug use by pregnant women remains a pervasive problem in American society. In 2002, 3% of all pregnant women aged 15 to 44 years exposed their fetus to 1 or more illicit drugs.1 Attempts to isolate effects attributable to a specific drug exposure, such as cocaine, have often been confounded by the use of multiple drugs and limited access to large varied populations. Drug abusers are mobile, difficult to track over time, and often noncompliant.2,3 From the mid-1980s into the early 1990s, a number of reports raised concerns about the potential teratogenic impact of fetal cocaine exposure during pregnancy. These observations included congenital anomalies,4,5 growth retardation,6-8 microcephaly,9,10 central nervous system infarction,11 seizures,12 cortical atrophy and cysts,13 intraventricular hemorrhage,14,15 various neurologic impairments,16,17 genitourinary tract and renal anomalies,18-20 gastrointestinal tract defects,21,22 limb deformities,23 and respiratory insufficiency including sudden infant death syndrome.24-27 A differential effect of drug exposure on preterm vs term infants has been suggested.28 More recent studies and systematic reviews have emphasized potential effects on long-term neurodevelopment, behavior, and learning29-33 while both the acute and chronic impacts of cocaine on growth remain.32,34,35 How race, sex, drug dose, sociodemographics, and other important modifying variables impact ultimate outcome has recently been considered.36,37Well-designed, prospective studies that fail to identify significant drug effects, ie, negative studies, may be published less often and therefore not referenced.38 This may result in a biased overreporting of less significant observations, as occurred in the early years of the crack and cocaine epidemic.

The Maternal Lifestyle Study (see page 833 for a list of institutions and investigators) was conceived and designed as a large multisite, prospective, randomized study, whose objective was to confirm or negate the null hypothesis that fetal cocaine exposure during pregnancy has no impact on acute maternal and infant medical outcomes, or on long-term neurodevelopmental infant outcomes.

Access to a large, multisite population was possible through the National Institute of Child Health and Human Development Neonatal Research Network, which, at the time the study was initiated, consisted of 12 major university research centers. The feasibility of successfully studying multicultural, multiethnic, sociodemographically varied populations with widespread use of drugs had been previously documented at several of the network participating centers.39-41 Four of the 12 network sites were selected by competitive peer review to participate in the Maternal Lifestyle Study. A wide range of acute medical outcomes in cocaine-exposed and nonexposed infants, including sociodemographic circumstances and polydrug use, were assessed in infants recruited at these sites. Acute maternal pregnancy outcomes in these cohorts have already been reported.42 This report presents identified associations between cocaine exposure during pregnancy and medical conditions in the newborn infant from birth through hospital discharge or death.


Recruitment and screening occurred during a 2-year period at 4 centers: Brown University, Providence, RI; the University of Miami, Miami, Fla; the University of Tennessee, Memphis; and Wayne State University, Detroit, Mich. Informed maternal consent and institutional review board approval were required for participation. Reasons for noneligibility and nonenrollment are listed in Figure 1. Mothers who consented were more likely to be black (50.5% vs 46.5%), to be unmarried (62.3% vs 56.5%), and to have a history of drug use (13.0% vs 9.3%). Mothers who identified themselves as white consented equally often (44.4% vs 44.9%) while those who responded that they were of “other” race consented at lower rates (5.1% vs 8.6%). Differences in preterm delivery rate, abruptio placentae, prenatal care, and use of Medicaid between those who consented and those who did not were small. All low-birth-weight infants (<1500 g) were screened. Maternal and infant charts were reviewed to identify obvious protocol exclusions. Informed consent was usually obtained before or within 24 hours of delivery.

Figure 1. 
Screening, enrollment, exclusions, eligibility, consent, and exposure identification. GC/MS indicates gas chromatography–mass spectroscopy.

Screening, enrollment, exclusions, eligibility, consent, and exposure identification. GC/MS indicates gas chromatography–mass spectroscopy.

Initial screening included the mother’s labor and delivery record, the newborn admission record, and a meconium sample. A detailed drug use questionnaire that addressed the mother’s use of nicotine, alcohol, marijuana, cocaine, opiates, and other illicit drugs was given by research staff trained and certified in the reliable administration of all the study interviews. A Department of Health and Human Services Certificate of Confidentiality allowed for strict confidentiality regarding all drug use information, including the 2 states (Florida and Rhode Island) that had mandatory reporting statutes. The certificate did not, however, circumvent required reporting of child abuse, sexual abuse, or neglect.

Although recruitment addressed exposure to cocaine and/or opiates, all analyses presented herein are limited to the cocaine-only and the non–cocaine-exposed cohorts.

Cocaine exposure was defined by maternal admission of cocaine use at any time during this pregnancy or a positive enzyme-multiplied immunoassay technique (EMIT) screen for cocaine metabolites in the infant’s meconium, confirmed by gas chromatography–mass spectroscopy, coupled with a negative EMIT screen for opiates. All analyses were performed by a central laboratory (El Sohly Laboratories Inc, Oxford, Miss)43 after informed consent was obtained. A history of cocaine use recorded in the medical record was not sufficient to qualify as exposed. Mothers who denied use, but in whom the infant’s meconium EMIT screen was positive and gas chromatography–mass spectroscopy analysis was not available, were excluded.44 A nonexposure designation required both a maternal denial of use and a negative result of meconium screening. There were 3183 infants of consenting mothers whose exposure could not be determined primarily because of lack of gas chromatography–mass spectroscopy confirmation. This included 2760 in whom meconium was unavailable, 254 in whom the quantity of meconium collected was insufficient for any analysis, and 169 with a positive EMIT screen but who had insufficient amounts of meconium for gas chromatography–mass spectroscopy confirmation. There was also 1 mother who withdrew consent. None of the mothers of these infants admitted cocaine use during pregnancy. Those mothers excluded because of indeterminate exposure were less likely to be black (47.5% vs 51.6%), were more likely to be married (40.7% vs 36.6%), and had a higher rate of preterm birth (7.8% vs 5.7%). As with mothers who refused consent, there were no important differences in their Medicaid insurance status, rate of prenatal care, or prevalence of abruptio placentae. Of the total 1072 infants with known exposure to cocaine, 717 (66.9%) were known to be exposed only to cocaine (Figure 1). The remaining cocaine-exposed infants were excluded as indeterminate. Use of alcohol, marijuana, and/or nicotine during pregnancy occurred in both groups (95% of those exposed, 42% of those nonexposed).

A standardized physical and neurologic examination, made up of 62 specific items and including the New Ballard Score,45 was performed within the first 24 hours of life by centrally trained and certified examiners from each site, who were masked to exposure status. Birth weight, length, and head circumference were measured and recorded. These same certified research personnel observed the “acute” course of these infants, which included the time from birth to infant death or discharge from the hospital. Seventy-seven individual conditions and/or diagnoses were recorded during the hospitalization. Detailed information on therapies, procedures, resuscitation, the length of stay, child protective services reporting, and proposed living situation was also collected. Information on medications administered to the mothers at delivery and complications of labor and delivery were assessed and reported previously.42

To compensate for and to protect against inflated type I error levels that may be caused by multiple comparisons, we decided a priori to report P<.01 as significant in these analyses. In addition, to reduce the number of reported outcomes and to eliminate redundancy, information from multiple sources was combined where this was deemed clinically valid, and outcomes with a prevalence of less than 1% in the nonexposed cohort and that had no occurrence in the cocaine-exposed cohort were dropped but are listed in the appropriate table footnotes. Outcome data were summarized by exposure groups, using frequency distributions (χ2 tests) or means and standard deviations (unpaired 2-tailed t tests) when appropriate. The estimated odds ratios and 99% confidence intervals are presented as a summary of the unadjusted relationship between cocaine-exposure status and each outcome.

Statistically significant (P<.01) bivariate associations were subjected to multivariate modeling to obtain covariate-adjusted estimates. Linear and logistic regression models were fitted for continuous and binary outcomes, respectively. A standard set of 10 covariates plus cocaine use, chosen a priori for all multivariate analyses, was as follows: clinical site; race or ethnicity; sex; birth weight; being small for gestational age; the use of alcohol, tobacco, or marijuana during pregnancy; maternal age; and maternal education. Tobacco exposure was categorized at 3 levels as high use (≥0.5 pack per day), low use (any other use), and no use. Alcohol was categorized into 3 groups: alcohol use with bingeing, nonbingeing alcohol use, and no alcohol use. Marijuana was entered as a simple yes-no use variable. Race or ethnicity of the mother was based on self-identification as black, Hispanic, or white/other. Maternal age was based on whether the mother was 26 years or older, or younger than 26 years, at the time of delivery. Maternal education (<12 years or ≥12 years) was considered a surrogate for socioeconomic status. Being small for gestational age was entered into the model to adjust for the enhanced effect of low birth weight seen primarily in the near-full-term subjects in the study. Being small for gestational age was based on a birth weight of less than 10th percentile for gestational age.46


Of the 19 079 women screened, 16 988 (89.0%) were eligible for recruitment, and 11 811 of those (69.5%) consented (Figure 1). Meconium was analyzed in 8804 infants (74.5%). There were 3184 excluded infants (27.0%). Meconium quantity was insufficient for any screening analysis in 2760 and in an additional 254 infants to confirm a positive EMIT screen; no meconium was collected in 169 infants, and 1 mother withdrew consent. Maternal self-report alone identified 7.5% of infants as cocaine exposed, and meconium analysis identified a 5.0% exposure rate (Table 1). The total cocaine-exposure rate was 9.1%. Meconium analysis identified an additional 190 exposed infants (1.6%) not acknowledged by self-report. Cocaine-exposure rates at the various sites ranged between 3.7% and 15.2%. The exposure rate in the low-birth-weight population (≤2500 g) was more than double that of normal-birth-weight infants (16.7% vs 6.7%). Of mothers who admitted cocaine use during pregnancy, meconium testing was confirmatory in 66.2% of the cases where both meconium and self-report were available. Because maternal admission alone was sufficient to define an infant as exposed, meconium screens and confirmations were not run on all of these infants. However, as noted already, an additional 1.6% of exposed infants, whose mothers denied use during pregnancy, were identified by meconium analysis.

Table 1. 
Cocaine Exposure by Source of Information, Birth Weight, Gestational Age, and Location of Clinic*
Cocaine Exposure by Source of Information, Birth Weight, Gestational Age, and Location of Clinic*

The 717 infants identified as exposed to cocaine only (Figure 1) were more often black (78.9% vs 46.3%) and their mothers were older (79.9% aged ≥ 26 years vs 48.3%) than the 7442 subjects in the nonexposed cohort (Table 2). The prevalence of prematurity (≤37 weeks’ gestation) was significantly greater in the cocaine-exposed cohort (42.6% vs 24.2%). Use of tobacco (81.8% vs 19.7%), alcohol (73.0% vs 30.6%), and marijuana (39.2% vs 5.0%) were all greater (P<.001) in the cocaine-exposed cohort.

Table 2. 
Characteristics of Subjects by Infant’s Drug Exposure Status*
Characteristics of Subjects by Infant’s Drug Exposure Status*

Table 3 lists the prevalence of specific physical findings and physiological observations assessed during the initial infant examination, as well as diagnoses and/or conditions observed during hospitalization. Abnormal physical findings were rare, with only tachypnea exceeding a 5% prevalence in either group. Two observations (flat philtrum and tachypnea) were significantly more frequent in the exposed cohort, but not after adjusting for covariates in a multivariable logistic regression model. The diagnoses of respiratory distress–transient tachypnea, apnea, retinopathy of prematurity, hepatitis, syphilis, human immunodeficiency virus–positive status, proven sepsis, and any infection were significantly more prevalent in the cocaine-exposed cohort. Hepatitis, syphilis, human immunodeficiency virus–positive status, and any infection remained significant after adjusting for covariates. These infections, determined during the hospitalization and based on laboratory confirmation, were consistent with the infection findings documented in the mothers.42

Table 3. 
Prevalence of Physical Findings and Symptoms Observed on Initial Physical Examination or During Hospitalization by Infant’s Drug Exposure Status*
Prevalence of Physical Findings and Symptoms Observed on Initial Physical Examination or During Hospitalization by Infant’s Drug Exposure Status*

Several central and autonomic nervous system findings, which included hypertonia, jitteriness or tremors, high-pitched cry, difficulty arousing, irritability, excessive suck, and hyperalertness, were noted more frequently on the initial physical examination in the cocaine-exposed cohort (Table 4). During the hospitalization, the diagnoses of seizures and autonomic instability were more frequently noted in cocaine-exposed infants. When adjusted, all of these findings except hypertonia, difficulty arousing, and seizures remained significant in the exposed cohort.

Table 4. 
Prevalence of CNS and ANS Findings and Symptoms Observed on Initial Physical Examination or by Chart Review at Death or Discharge by Infant’s Drug Exposure Status*
Prevalence of CNS and ANS Findings and Symptoms Observed on Initial Physical Examination or by Chart Review at Death or Discharge by Infant’s Drug Exposure Status*

More screening and diagnostic echocardiograms of the heart, abdomen, and head were performed in the exposed cohort (odds ratio, 1.54; 99% confidence interval, 1.01-2.34) (Table 5), explained primarily by lower-birth-weight infants in that group. In addition, they were ordered by the infant’s primary caretakers, who were usually aware of the infant’s exposure status as well as the early literature that suggested that anatomic abnormalities might be associated with intrauterine cocaine exposure. Despite this increased surveillance, no ultrasound diagnoses were more prevalent in the cocaine-exposed group.

Table 5. 
Screening and/or Diagnostic ECHO Examinations Performed*
Screening and/or Diagnostic ECHO Examinations Performed*

The cocaine-exposed infants were significantly smaller (P<.001) in all growth measures before and after adjustment (Table 6). They were 536 g lighter at birth, were 2.6 cm shorter, and had a 1.5-cm smaller head circumference. Gestational age was significantly lower by 8.4 days (1.2 weeks) in the cocaine-exposed group (as measured by the revised Ballard examination45). The prevalence of being small for gestational age was more than double in the cocaine-exposed cohort (29.4% vs 13.5%). The relationship between birth weight and gestational age is complex. Figure 2 displays that relationship by contrasting birth weights at various gestational ages in the 2 study groups on the basis of the birth weight categories (501-1500, 1501-2500, and >2500 g). The negative effect of cocaine exposure was most evident in the heavier, later-gestation infants.

Figure 2. 
Birth weights by gestational ages (using best obstetric estimate) in the 2 study groups within birth weight categories (501-1500 g, 1501-2500 g, and >2500 g).

Birth weights by gestational ages (using best obstetric estimate) in the 2 study groups within birth weight categories (501-1500 g, 1501-2500 g, and >2500 g).

Table 6. 
Growth and Gestational Age Measures on Newborn Initial Physical Examination by Infant’s Drug Exposure Status
Growth and Gestational Age Measures on Newborn Initial Physical Examination by Infant’s Drug Exposure Status

Delivery room resuscitation and intubation occurred more frequently in the cocaine-exposed infants (Table 7). Similarly, exposed infants received more therapies and underwent more procedures, but adjustment for other explanatory factors eliminated these differences. Cocaine-exposed infants were less often breastfed even after correcting for the birth weight differences between exposed and nonexposed infants. The increased admissions of exposed infants to neonatal intensive care or special care units was again related to the higher prevalence of low-birth-weight infants in the exposed cohort. There was no difference in survival (99.6% vs 99.7%), but the duration of hospitalization for infants who died (13.0 vs 56.2 days) was significantly shorter (P = .008) for the cocaine-exposed infants, again explained primarily by the birth weight disparity between the 2 groups. Exposed infants who survived were 48 times more likely to be kept in the hospital, labeled as “boarder infants,” resulting in extended hospital stays (17.6% vs 0.5%) (Table 7).

Table 7. 
Procedures and Treatments During Hospitalization and Discharge or Death Information by Infant’s Drug Exposure Status
Procedures and Treatments During Hospitalization and Discharge or Death Information by Infant’s Drug Exposure Status

Exposed infants were 49 times more likely to be involved with child protective services (38.5% vs 1.0%) and 19 times more often were discharged to the care of someone other than their mothers (18.8% vs 1.0%). Mothers of exposed infants were 6 times more likely to consider adoption as a permanent placement for their infants (2.1% vs 0.4%) (Table 8).

Table 8. 
Infant CPS Involvement and Living Situation at Discharge by Infant’s Drug Exposure Status
Infant CPS Involvement and Living Situation at Discharge by Infant’s Drug Exposure Status


The teratogenic and toxic potential of fetal exposure to cocaine remains controversial. The Maternal Lifestyle Study attempted to clarify some of the ambiguity surrounding this important public health problem. The strengths of this study include its large sample size and extensive training and certification of research teams at each site to ensure consistency and reliability of both assessments and data collection. The multisite nature of this collaboration provided a multicultural, multiethnic population that included broad-based sociodemographic characteristics. The definition of cocaine-exposure status was reliable, based on self-report of cocaine use during pregnancy or demonstration of cocaine metabolites in meconium by means of state-of-the-art technology performed by a centralized facility. Testing of meconium, rather than urine, is hypothesized to reliably detect drug metabolites over a longer period of use during pregnancy. An additional 190 cocaine-exposed infants were identified by meconium analysis from mothers who denied drug use. There was no incentive to falsely admit the use of an illegal substance; however, the reverse was not true. Therefore, a negative meconium sample was required for the definition of nonexposure in mothers who denied use.

The important issues of multiple exposures to alcohol, tobacco, and/or marijuana, as well as the level of their use, were specifically addressed with the multivariate analyses. Both study cohorts had significant exposures to these 3 drugs, with more than 40% of the non–cocaine-exposed mothers also admitting to use. The impact of socioeconomic status and of a drug culture environment on outcome is complex, but important confounders and these variables were also addressed in the analyses. Unfortunately, not all potential confounders were eliminated. Since consent was required, it remains possible that particularly heavy users or those who used multiple drugs might be more likely to refuse participation. Because mothers were enrolled at or around the time of delivery, substance use early in pregnancy could have escaped detection.

This study contradicts the early reports of an increased prevalence of congenital anomalies. The increased central and autonomic nervous system dysfunction seen in the exposed cohort was mild, including soft signs such as irritability, jitteriness, tremors, high-pitched cry, and excessive suck. Although the cocaine-exposed cohort included more premature, low-birth-weight infants, who often exhibit mild, transient neurologic findings, most of the central nervous system findings remained significant after adjusting for birth weight, suggesting a true cocaine effect as reported by Chiriboga et al.13,16 These rather subtle, acute neurologic findings support the findings of more recent reports, which suggest potential long-term neurodevelopmental, behavioral, and learning effects of cocaine exposure, rather than any acute teratogenic impact. More ultrasound examinations were ordered by the primary physician in the exposed cohort. The higher prevalence of premature infants in the exposed cohort, who have more complex illnesses, longer hospital stays, and more diagnostic tests such as echocardiograms, may also help to explain this difference. It is also true, however, that the clinicians who ordered these examinations were often aware of the infant’s exposure status as well as the literature that equated cocaine exposure with the possible teratogenicity of various organ systems. Of note is that the ultrasound studies of the head were read centrally by expert ultrasonographers who were masked to exposure status. However, despite this heightened scrutiny, no differential structural abnormalities of the heart, gastrointestinal tract, kidneys, or brain were documented by these detailed examinations. These findings strongly support the conclusion that cocaine has no obvious anatomic teratogenic impact.

All measures of growth were affected by cocaine exposure, and this growth restriction was most evident in the larger, more mature infants. Growth failure as gestation progresses may relate to the vasoconstrictive impact of cocaine on the normally aging placenta, accelerating its demise and resulting in not only shorter gestations (prematurity) but also in increasing overall growth inhibition (small for gestational age) as term approaches.

An extremely important finding of this study is the increased prevalence of infectious diagnoses, particularly sexually associated infections that were previously reported in these mothers.42 Although human immunodeficiency virus–positive exposure status had a very low overall prevalence in this study (0.1%), it occurred almost 16 times more often in infants born to cocaine-abusing women, a clear documentation of the increased risk of an often fatal infection. Similarly, a diagnosis of hepatitis occurred about 42 times more often in cocaine-exposed infants, and syphilis was 15 times as common. The morbidity and mortality associated with these diseases may have a significant impact on both health care utilization and long-term developmental outcome. The increased use of both medical (intensive care, procedures, therapies, length of stay, etc) and social (referrals to child protective services, adoption, and foster care) services by the cocaine-exposed cohort is significant. The hospital utilization findings are reflective of cocaine’s effect on both gestation and birth weight, whereas the social impact as reflected through child protective services involvement and the infant’s living situation is a direct effect of the mother’s cocaine use. The serious infectious exposures associated with prenatal cocaine abuse and the burden and cost imposed on the criminal and social justice systems are important short-term outcomes that have obvious long-term implications and have not been previously addressed. Being classified as a boarder infant was 48 times more likely in cocaine-exposed infants, resulting in extended hospital stays. Cocaine-exposed infants were 49 times more likely to be involved with child protective services and 17 times more likely to be placed in foster care. Adoption was a seriously considered option for 6 times as many cocaine-abusing women. The manpower and fiscal impact of these social risks on society are significant.

Prenatal exposure to cocaine has a different face than had been previously emphasized. It does not result in obvious and marked fetal damage, but rather, as recent reports suggest, a more subtle impact has evolved.47 Significant societal expenditures will continue to be required to address the social, environmental, and developmental issues of children born to mothers engaged in the drug abuser’s lifestyle.

Cocaine use by women during pregnancy with resultant fetal exposure is preventable, but the degree of disability that may result from a particular exposure must be clarified to mobilize resources to respond effectively and efficiently. Long-term issues regarding the impact of cocaine exposure on cognition, learning, neurodevelopment, behavior, emotional stability, and potential infectious morbidity are important and clinically relevant. The Maternal Lifestyle Study is currently engaged in examining these late outcome issues as part of an 11-year follow-up.


Maternal Lifestyle Study Institutions and Investigators

Brown University, Providence, RI: Barry M. Lester, PhD; Linda LaGassee, PhD; Susan Schibler, RN; Melissa Ambrosia, RN. University of Miami, Miami, Fla: Charles R. Bauer, MD; Wendy Griffin, RN; Elizabeth Jacque, RN. University of Tennessee, Memphis: Henrietta S. Bada, MD; Marilyn Williams, MSW; Tina Hudson, BSN. Wayne State University, Detroit, Mich: Seetha Shankaran, MD; Eunice Woldt, MSN; Jay Ann Nelson, BSN. The George Washington University Biostatistics Center, Rockville, Md: Joel Verter, PhD; Heidi Krause-Steinrauf, MS. Research Triangle Institute International, Research Triangle Park, NC: W. Kenneth Poole, PhD; John Langer, MSc; Jane Hammond, MA; Ann Bowler, MS. National Institute on Child Health and Human Development, Bethesda Md: Linda L. Wright, MD. National Institute on Drug Abuse, Bethesda: Vincent L. Smeriglio, PhD. Administration on Children, Youth and Families, Washington, DC: Penelope L. Maza, PhD. The Center for Substance Abuse Treatment, Washington: Loretta P. Finnegan, MD.

Correspondence: Charles R. Bauer, MD, Department of Pediatrics (R-131), University of Miami, PO Box 016960, Miami, FL 33101.

Back to top
Article Information

Accepted for Publication: March 3, 2005.

Funding/Support: This study was supported by the National Institute of Child Health and Human Development, Bethesda, Md, through cooperative agreements (U10 HD 21397, U01 HD 2367902, U10 HD 213853, U10 HD 214154, U10 HD 279045, and U01 HD 198977), as well as intra-agency agreements with the National Institute on Drug Abuse, Bethesda; Administration on Children, Youth, and Families, Washington, DC; and the Center for Substance Abuse Treatment, Washington.

Acknowledgment: We thank Elisabeth Ravelo for the preparation of this manuscript and Abik Das and W. Kenneth Poole of Research Triangle Institute for their assistance and review of the manuscript.

Substance Abuse and Mental Health Services Administration, Results from the 2002 National Survey on Drug Use and Health: National Findings.  Rockville, Md Office of Applied Studies2003;NHSDA Series 11-22, DHHS publication SMA 03-3836
Azuma  SDChasnoff  IJ Outcome of children prenatally exposed to cocaine and other drugs: a path analysis of three-year data.  Pediatrics 1993;92396- 402PubMedGoogle Scholar
Lester  BMLaGasse  LBrunner  S Data base of studies on prenatal cocaine exposure and child outcome.  J Drug Issues 1997;27487- 499Google Scholar
Bingol  NFuchs  MDiaz  VStone  RKGromisch  DS Teratogenicity of cocaine in humans.  J Pediatr 1987;11093- 96PubMedGoogle ScholarCrossref
Finnell  RHToloyan  Svan Waes  M Preliminary evidence for a cocaine-induced embryopathy in mice.  Toxicol Appl Pharmacol 1990;103228- 237PubMedGoogle ScholarCrossref
Frank  DABauchner  HParker  S  et al.  Neonatal body proportionality and body composition after in utero exposure to cocaine and marijuana.  J Pediatr 1990;117622- 626PubMedGoogle ScholarCrossref
Coles  CDPlatzman  KASmith  IJames  MAFalek  A Effects of cocaine and alcohol use in pregnancy on neonatal growth and neurobehavioral status.  Neurotoxicol Teratol 1992;1423- 33PubMedGoogle ScholarCrossref
Weathers  WTCrane  MMSauvain  KJBlackhurst  DW Cocaine use in women from a defined population: prevalence at delivery and effects on growth in infants.  Pediatrics 1993;91350- 354PubMedGoogle Scholar
Little  BBSmith  LM Brain growth among fetuses exposed to cocaine in utero: asymmetrical growth retardation.  Obstet Gynecol 1991;77361- 364PubMedGoogle Scholar
Sallee  FRKatikaneni  LPMcArthur  PDIbrahim  HMNesbitt  LSethuraman  G Head growth in cocaine-exposed infants: relationship to neonate hair level.  J Dev Behav Pediatr 1995;1677- 81PubMedGoogle ScholarCrossref
Chasnoff  IJBussey  MESavich  RStack  CM Perinatal cerebral infarction and maternal cocaine use.  J Pediatr 1986;108456- 459PubMedGoogle ScholarCrossref
Kramer  LDLocke  GEOgunyemi  A Neonatal cocaine-related seizures.  J Child Neurol 1990;560- 64PubMedGoogle ScholarCrossref
Chiriboga  CABateman  DABrust  JCHauser  WA Neurologic findings in neonates with intrauterine cocaine exposure.  Pediatr Neurol 1993;9115- 119PubMedGoogle ScholarCrossref
McLenan  DAAyayi  OARydman  RJPildes  RS Evaluation of the relationship between cocaine and intraventricular hemorrhage.  J Natl Med Assoc 1994;86281- 287PubMedGoogle Scholar
Singer  LTYamashita  TSHawkins  SCairns  DBaley  JKliegman  R Increased incidence of intraventricular hemorrhage and developmental delay in cocaine-exposed, very low birth weight infants.  J Pediatr 1994;124765- 771PubMedGoogle ScholarCrossref
Chiriboga  CAVibbert  MMalouf  R  et al.  Neurological correlates of fetal cocaine exposure: transient hypertonia of infancy and early childhood.  Pediatrics 1995;961070- 1077PubMedGoogle Scholar
King  TAPerlman  JMLaptook  ARRollins  JJackson  GLittle  B Neurologic manifestations of in utero cocaine exposure in near term and term infants.  Pediatrics 1995;96259- 264PubMedGoogle Scholar
Chasnoff  IJChisum  GMKaplan  WE Maternal cocaine use and genitourinary tract malformations.  Teratology 1988;37201- 204PubMedGoogle ScholarCrossref
Chavez  GFMulinare  JCordero  JG Maternal cocaine use during early pregnancy as a risk factor for congenital urogenital anomalies.  JAMA 1989;262795- 798PubMedGoogle ScholarCrossref
Rosenstein  BJWheeler  JSHeid  PL Congenital renal abnormalities in infants with in-utero cocaine exposure.  J Urol 1990;144110- 112PubMedGoogle Scholar
Porat  RBrodsky  N Cocaine: a risk factor for necrotizing enterocolitis.  J Perinatol 1991;1130- 32PubMedGoogle Scholar
Telsey  AMMerrit  TADixon  SD Cocaine exposure in a term neonate: necrotizing enterocolitis as a complication.  Clin Pediatr (Phila) 1988;27547- 550PubMedGoogle ScholarCrossref
Hoyme  HEJones  KLDixon  SD  et al.  Prenatal cocaine exposure and fetal vascular disruption.  Pediatrics 1990;85743- 747PubMedGoogle Scholar
Chen  CDuara  SSilva Neto  G  et al.  Respiratory instability in neonates with in utero exposure to cocaine.  J Pediatr 1991;119111- 113PubMedGoogle ScholarCrossref
Hand  ILNoble  IMcVeigh  JJKim  MYoon  JJ The effects of intrauterine cocaine exposure on the respiratory status of the very low birth weight infant.  J Perinatol 2001;21372- 375PubMedGoogle ScholarCrossref
Bauchner  HZuckerman  B Cocaine, sudden infant death syndrome, and home monitoring.  J Pediatr 1990;117904- 906PubMedGoogle ScholarCrossref
Silvestri  JMLong  JMWeese Mayer  DEBarkov  GA Effect of prenatal cocaine on respiration, heart rate, and sudden infant death syndrome.  Pediatr Pulmonol 1991;11328- 334PubMedGoogle ScholarCrossref
Brown  JVBakeman  RColes  SDSexton  WRDemi  AS Maternal drug use during pregnancy: are preterm and full-term infants affected differently?  Dev Psychol 1998;34540- 554PubMedGoogle ScholarCrossref
Singer  LArendt  RFarkas  KMinnes  SHuang  JYamashita  T Relationship of prenatal cocaine exposure and maternal postpartum psychological distress to child developmental outcome.  Dev Psychopathol 1997;9473- 489PubMedGoogle ScholarCrossref
Held  JRRiggs  MLDorman  C The effect of prenatal cocaine exposure on neurobehavioral outcome: a meta-analysis.  Neurotoxicol Teratol 1999;21619- 625PubMedGoogle ScholarCrossref
Espy  KAFrancis  DJRiese  ML Prenatal cocaine exposure and prematurity: neurodevelopmental growth.  J Dev Behav Pediatr 2000;21262- 270PubMedGoogle ScholarCrossref
Frank  DAAugustyn  MGrant Knight  WPell  TZuckerman  B Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review.  JAMA 2001;2851613- 1625PubMedGoogle ScholarCrossref
Eiden  RDLewis  ACroff  SYoung  E Maternal cocaine use and infant behavior.  Infancy 2002;377- 96Google ScholarCrossref
Eyler  FDBehnke  MConlon  MWoods  NSWobie  K Birth outcome from a prospective, matched study of prenatal crack/cocaine use, 1: interactive and dose effects on health and growth.  Pediatrics 1998;101229- 237PubMedGoogle ScholarCrossref
Bandstra  ESMorrow  CEAnthony  JC  et al.  Intrauterine growth of full-term infants: impact of prenatal cocaine exposure.  Pediatrics 2001;1081309- 1319PubMedGoogle ScholarCrossref
LaGasse  LLSeifer  RLester  BM Interpreting research on prenatal substance exposure in the context of multiple confounding factors.  Clin Perinatol 1999;2639- 54PubMedGoogle Scholar
Frank  DAJacobs  RRBeeghly  M  et al.  Level of prenatal cocaine exposure and scores on the Bayley Scales of Infant Development: modifying effects of caregiver, early intervention and birth weight.  Pediatrics 2002;1101143- 1152PubMedGoogle ScholarCrossref
Koren  GGraham  KShear  HEinarson  T Bias against the null hypothesis: the reproductive hazards of cocaine.  Lancet 1989;21440- 1442PubMedGoogle ScholarCrossref
Bandstra  ESBurkett  G Maternal-fetal and neonatal effects of in utero cocaine exposure.  Semin Perinatol 1991;15288- 301PubMedGoogle Scholar
Jacobson  SWJacobson  JLSokol  RJMartin  SSAger  JWKaplan  MG Maternal recall of alcohol, cocaine, and marijuana use during pregnancy.  Neurotoxicol Teratol 1991;13535- 540PubMedGoogle ScholarCrossref
Lester  BMCorwin  MJSepkoski  C  et al.  Neurobehavioral syndromes in cocaine exposed newborn infants.  Child Dev 1991;62694- 705PubMedGoogle ScholarCrossref
Bauer  CRShankaran  SBada  HS  et al.  The Maternal Lifestyle Study: drug exposure during pregnancy and short-term maternal outcomes.  Am J Obstet Gynecol 2002;186487- 495PubMedGoogle ScholarCrossref
ElSohly  MAStanford  DFMurphy  TP  et al.  Immunoassay and GC-MS procedures for the analysis of drugs of abuse in meconium.  J Anal Toxicol 1999;23436- 445PubMedGoogle ScholarCrossref
Lester  BMElSohly  MWalls  HC  et al.  The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report.  Pediatrics 2001;107309- 317PubMedGoogle ScholarCrossref
Ballard  JKhoury  JCWedig  KWang  LEiters-Walsman  BLLipp  R New Ballard Score, expanded to include extremely premature infants.  J Pediatr 1991;119417- 423PubMedGoogle ScholarCrossref
Alexander  GRHines  JHKaufman  RBMor  JKogan  M A United States national reference for fetal growth.  Obstet Gynecol 1996;87163- 167PubMedGoogle ScholarCrossref
Lester  BMLaGasse  LLSeifer  R Cocaine exposure and children: the meaning of subtle effects.  Science 1998;282633- 634PubMedGoogle ScholarCrossref